Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q2 FY2026 Earnings Presentation
23 slides from Aurobindo Pharma's earnings presentation, Nov 5, 2025
Slide 1: Covering letter to stock exchanges
November 5, 2025 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q2FY26
Aurobindo Pharma Limited Earnings Presentation Q2FY26
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Content
Table of Content 04 Q2FY26 Business & Financial Highlights 11 Update on Biosimilars 16 Financial Summary 13 19 Filings Snapshot 3
Slide 5: Q2FY26 Business & Financial Highlights
Q2FY26 Business & Financial Highlights 4
Slide 6: Key Financial Highlights of the Quarter
Key Financial Highlights of the Quarter Revenue EBITDA Net Profit Q2FY26 ₹ 8,286 Cr ₹ 1,678 Cr ₹ 848 Cr Q2FY25 ₹ 7,796 Cr ₹ 1,566 Cr ₹ 817 Cr Y-o-Y growth % 6.3% 7.1% 3.8% 55
Slide 7: Business Highlights – Q2FY26
Business Highlights – Q2FY26 Revenue of ₹8,286 crores with 6.3% growth YoY, driven by strong US, Europe and Growth Markets performance Reported EBITDA of ₹1,678 crores with a margin of 20.3%, driven by stable gross margins and operating efficiencies Net Capex of US$ 106 million* primarily towards ca
Slide 8: Quarterly Performance – Q2FY26
Quarterly Performance – Q2FY26 Revenue (Rs Crore) US Revenue excluding Puerto Rico (US$ Mn) 8,382 470 8,286 7,979 435 7,868 426 7,796 421 417 7,567 408 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q2FY26 EBITDA (Rs Crore) Cash flows before dividend and buyback ($ Mn)
Slide 9: Consolidated Business Performance
Consolidated Business Performance ₹ Crores Q2FY26 Q2FY25 Y-o-Y (%) Q1FY26 Q-o-Q (%) USA 3,638 3,530 3.1% 3,488 4.3% Europe 2,480 2,105 17.8% 2,338 6.1% Growth Markets* 882 812 8.7% 772 14.3% ARV 325 193 68.7% 355 -8.3% Total Formulations 7,325 6,640 10.3% 6,953 5.4% Beta-lactam 668 837 -20.1% 633 5.
Slide 10: US Formulations Business Performance Highlights (Excluding Puerto Rico)
US Formulations Business Performance Highlights (Excluding Puerto Rico) Revenue (US$ Mn) Commentary 440 • US revenue in Q2FY26 increased by 2% QoQ 421 417 accounting for 43.9% of consolidated revenue 420 408 driven by strong growth in base business 400 despite lower transient product sales 380 • Exc
Slide 11: Revenue Break-up by Business
Revenue Break-up by Business Europe (EUR Mn) Growth Markets (US$ Mn) ARV (US$ Mn) API (₹ Crore) 1,156 243 101 241 97 961 229 90 916 41 37 23 Q2FY25 Q1FY26 Q2FY26 Q2FY25 Q1FY26 Q2FY26 Q2FY25 Q1FY26 Q2FY26 Q2FY25 Q1FY26 Q2FY26 Growth Markets reported a YoY Europe business posted ARV business continued
Slide 12: Update on Biosimilars
Update on Biosimilars 11
Slide 13: Sustaining the Momentum in Biosimilars
Sustaining the Momentum in Biosimilars Delivered biosimilar • Three biosimilar products, including trastuzumab biosimilar, approved by approvals across key markets European Commission, EU. (European Commission, • Four biosimilar products including two monoclonal antibodies – bevacizumab MHRA UK). an
Slide 14: Approved Products Portfolio
Approved Products Portfolio ▪ Portfolio includes pegfilgrastim, filgrastim, trastuzumab, bevacizumab biosimilars with strong regulatory validation. ▪ SKU expansions planned to broaden patient access. ▪ Future launches targeting additional therapeutic indications to deepen market penetration. 13
Slide 15: Evolving Regulatory, Manufacturing and Supply Chain Strategy
Evolving Regulatory, Manufacturing and Supply Chain Strategy Regulatory & Geographic Manufacturing Capacity & Supply Expansion Strategy Chain Strategy • Ongoing marketing applications under • Capacity expansion underway in both review with Health Canada. filling and bulk drug substance manufacturing
Slide 16: Strategic Outlook and Growth Priorities
Strategic Outlook and Growth Priorities Accelerate post-2028 pipeline advancement with high-potential biosimilars. Invest in manufacturing capacity enhancement and capabilities to maintain competitive edge. Forge strategic partnerships to enhance biosimilars commercialization and global reach. Execu
Slide 17: Financial Summary
Financial Summary 16
Slide 18: Summary Consolidated Profit & Loss Statement
Summary Consolidated Profit & Loss Statement Rs Cr Q2FY26 Q2FY25 YoY Chg. (%) Q1FY26 QoQ Chg. (%) Revenue from Operations 8,286 7,796 6.3% 7,868 5.3% Gross Profit 4,947 4,586 7.9% 4,629 6.9% Gross Margin 59.7% 58.8% 88 bps 58.8% 87 bps Overheads -3,269 -3,020 8.2% -3,025 8.0% EBITDA (before Forex an
Slide 19: Debt Profile
Debt Profile Gross Debt (US$ Mn) Debt as on (INR Cr) Mar-22 Mar-23 Mar-24 Mar-25 Sep-25 Closing Rate (INR/USD) 75.793 82.170 83.405 85.475 88.79 833 966 963 930 884 843 Fx Loan restated in INR 2,223 4,638 3,994 5,883 5,720 Rupee Loan 150 224 2,324 2,065 1,764 232 228 182 185 196 117 Gross Debt 2,373
Slide 20: Filing Snapshot
Filing Snapshot 19
Slide 21: US ANDA Filings Snapshot as on 30th September 2025
US ANDA Filings Snapshot as on 30th September 2025 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ CNS 160 29.6 Aurobindo (Excl. Specialty & 800 711 600 539 Specialty & Injectables 300 700 ARV 30 1.6 600 500 250 500 200 172 Injectables) 400 400 150 51.9 300 300 CVS 124 200 134 200 106 1
Slide 22: Global Regulatory Filing Details
Global Regulatory Filing Details As at As at As at As at As at As at As at As at As at Category Geography Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 Mar 24 Mar 25 Jun 25 Sep 25 US* 541 586 639 727 774 830 861 865 876 Europe** 3,003 3,214 3,374 3,580 3,751 3,642 3,933 3,985 4,202 Formulations SA** 430 436 34
Slide 23: Thank You
Thank You Digitally signed by BADDIGAM ADI REDDY Date: 2025.11.05 19:45:54 +05'30' For more information, contact: ir@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 1211 2222